A phase i study of Triapine® in combination with doxorubicin in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 6, 2009, Pages 1147-1156

  Schelman, William R ^a   Morgan Meadows, Sherry ^b   Marnocha, Rebecca ^a   Lee, Fred ^a   Eickhoff, Jens ^a   Huang, Wei ^a   Pomplun, Marcia ^a   Jiang, Zhisheng ^a   Alberti, Dona ^a   Kolesar, Jill M ^a   Ivy, Percy ^c   Wilding, George ^a   Traynor, Anne M ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b Southern Cancer Center   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

3 Aminopyridine 2 carboxaldehyde thiosemicarbazone; Doxorubicin; Phase I; Ribonucleotide reductase; Triapine

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; DOXORUBICIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER FATIGUE; CANCER PATIENT; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HEART FAILURE; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; HYPOXIA; INJECTION SITE REACTION; KIDNEY FAILURE; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; METHEMOGLOBINEMIA; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PYRIDINES; THIOSEMICARBAZONES;

EID: 63949084997     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0890-8     Document Type: Article

References (33)

1. JG Cory AH Cory G Rappa A Lorico MC Liu TS Lin AC Sartorelli 1994 Inhibitors of ribonucleotide reductase. Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones Biochem Pharmacol 48 335 344
2. AB Alvero W Chen AC Sartorelli P Schwartz T Rutherford G Mor 2006 Triapine (3-amino-2-carboxaldehyde thiosemicarbazone) Induces Apoptosis in Ovarian Cancer Cells J Soc Gynecol Investig 13 2 145 152
3. HL Elford M Freese E Passamani HP Morris 1970 Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas J Biol Chem 245 5228 5233
4. Y Yu J Wong DB Lovejoy DS Kalinowshi DR Richardson 2006 Chelators at the cancer coalface: desferrioxamine to Triapine and beyond Clin Cancer Res 12 23 6876 6883
5. P Nordlund B-M Sjoberg H Eklund 1990 Three-dimensional structure of the free radical protein of ribonucleotide reductase Nature 345 593 598
6. Cory JG, Chiba P (1989) Combination chemotherapy directed at the components of nucleoside diphosphate reductase. In: Cory JG, Cory AM (eds) International encyclopedia of pharmacology and therapeutics-inhibitors of ribonucleotide diphosphate reductase activity. Pergamon Press, NY, pp 245-264 Sect. 128
7. JA Wright AK Chan BK Choy 1990 Regulation and drug resistance mechanisms of mammalian ribonucleotide reductase, and the significance to DNA synthesis Biochem Cell Biol 68 1364 1371
8. Antholine WE, Lyman S, Petering DH, Pickart L (1985) In: Karlin KD, Zubieta J (eds) Biological and inorganic copper complexes. Adenine Press, USA, pp 125-137
9. DR Richardson 2006 Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity J Med Chem 49 6510 6521
10. J Shao B Zhou B Chu Y Yen 2006 Ribonucleotide reductase inhibitors and future drug design Curr Cancer Drug Targets 6 5 409 431
11. J Shao B Zhou AJ Di Bilio L Zhu T Wang C Qi J Shih Y Yen 2006 A ferrous-triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase Mol Cancer Ther 5 586 592
12. RA Finch M Liu SP Grill WC Rose R Loomis KM Vasquez Y Cheng AC Sartorelli 2000 Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity Biochem Pharmacol 59 983 991
13. L Feun M Modiano K Lee J Mao A Marini N Savaraj P Plezia B Almassian E Colacino J Fischer S MacDonald 2002 Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule Cancer Chemother Pharmacol 50 223 229
14. J Murren M Modiano C Clairmont P Lambert N Savaraj T Doyle M Sznol 2003 Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors Clin Cancer Res 9 4092 4100
15. FJ Giles PM Fracasso HM Kantarjian JE Cortes RA Brown S Verstovsek Y Alvarado DA Thomas S Faderl G Garcia-Manero LP Wright T Samson A Cahill P Lambert W Plunkett M Sznol JF DiPersio V Gandhi 2003 Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia Leuk Res 27 12 1077 1083
16. Dorr RT, Van Hoff DD (1994) Cancer chemotherapy handbook, 2nd edn. Appleton and Lange, pp 500-514, 524-526
17. EH Rubin DP de Alwis I Pouliquen L Green P Marder Y Lin R Musanti SL Grospe SL Smith DL Toppmeyer J Much M Kane A Chaudhary C Jordan M Burgess CA Slapak 2002 A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies Clin Cancer Res 8 12 3710 3717
18. S Attia J Kolesar MR Mahoney HC Pitot D Laheru J Heun W Huang J Eickhoff C Erlichman KD Holen 2008 A phase 2 consortium (P2C) trial of 3 aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas Invest New Drugs 26 4 369 379
19. Kolesar J, Huang W, Eickhoff J, Hahn K, Alberti D, Attia S, Schelman W, Holen K, Traynor A, Ivy P, Wilding G (2008) Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors. Cancer Chemother Pharmacol. doi: 10.1007/s00280-008-0845-0
20. Greeno E, Kindler HL, Peeters M, Trowbridge RC, Chong G, Valle JW, Johnson B, Allain EL, Burris HA (2006) A phase II study of triapine in combination with gemcitabine (G) in patients (pts) with unresectable or metastatic pancreatic cancer (PC). JCO. 2006 ASCO annual meeting proceedings part I. vol 24, no. 18S (June 20 Supplement): 4123
21. Prod Info Adriamycin RDF(R)/PFS(R), 2000
22. RH Blum SK Carter 1974 Adriamycin. A new anticancer drug with significant clinical activity Ann Intern Med 80 2 249 259
23. AU Buzdar C Marcus TL Smith GR Blumenschein 1985 Early and delayed clinical cardiotoxicity of doxorubicin Cancer 55 12 2761 2765
24. RG Watts 1991 Severe and fatal anthracycline cardiotoxicity at cumulative doses below 400 mg/m2: evidence for enhanced toxicity with multiagent chemotherapy Am J Hematol 36 3 217 218
25. G Bepler S Sharma A Cantor 2004 RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer J Clin Oncol 22 1878 1885
26. G Bepler I Kusmartseva S Sharma A Gautam A Cantor A Sharma G Simon 2006 RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer J Clin Oncol 28 4731 4736
27. YG Goan B Zhou E Hu S Mi Y Yen 1999 Overexpression of ribonucleotide reductase as a mechanism of resistance to 2, 2-difluorodeoxycytidine in the human KB cancer cell line Cancer Res 59 4204 4207
28. S Tanno Y Nakano K Koizumi 2007 Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells Br J Cancer 96 457 463
29. WH Lewis PR Srinivasan 1983 Chromosome-mediated gene transfer of hydroxyurea resistance and amplification of ribonucleotide reductase activity Mol Cell Biol 3 1053 1061
30. JM Cocking PN Tonin NM Stokoe EJ Wensing WH Lewis PR Srinivasan 1987 Gene for M1 subunit of ribonucleotide reductase is amplified in hydroxyurea- resistant hamster cells Somatic Cell Mol Genet 13 221 233
31. GA McClarty AK Chan JA Wright 1986 Characterization of a mouse cell line selected for hydroxyurea resistance by a stepwise procedure: drug-dependent overproduction of ribonucleotide reductase activity Somatic Cell Mol Genet 12 121 131
32. RA Finch M Liu SP Grill 2000 Triapine (3-aminopyridine-2- carboxaldehydethiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broadspectrum antitumor activity Biochem Pharmacol 59 983 991
33. R Kayyali JB Porter ZD Liu 2001 Structure-function investigation of the interaction of 1- and 2-substituted 3-hydroxypyridin-4-ones with 5-lipoxygenase and ribonucleotide reductase J Biol Chem 276 48814 48822